test
test
test
test
test
test
test
test
test
test
There are 2 speakers in this webinar
The video talks about the personalization of BPH/LUTS medications as per the clinical situation or complication.
The video talks about the personalization of BPH/LUTS medications as per the clinical situation or complication.
The video talks about the personalization of BPH/LUTS medications as per the clinical situation or complication.
Dr N Mallikarjuna takes us through the various consensus statements and their evidence. These statements helped in creating an Algorithmic approach to...
Dr N Mallikarjuna takes us through the various consensus statements and their evidence. These statements helped in creating an Algorithmic approach to...
Dr N Mallikarjuna takes us through the various consensus statements and their evidence. These statements helped in creating an Algorithmic approach to...
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process. Dr. Anwar Ali discusses the tips and tricks for RIRS.
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process. Dr. Anwar Ali discusses the tips and tricks for RIRS.
Retrograde Intra-Renal Surgery (RIRS) is a minimally invasive process. Dr. Anwar Ali discusses the tips and tricks for RIRS.
A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
According to a recent study, the administration of fifty mg of Vibegron once daily for twelve weeks exhibited significant improvement in bladder storage symptoms related to overactive bladder (OAB) following laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period. The findings of this study were published in the journal, Lower Urinary Tract Symptoms.Split into two groups: one group received Vibegron 50 mg once daily, while the other group had no treatment and were only followed up for 12 weeks.The median age (interquartile range) was 75.5 (72.5-78.5) years for the Vibegron group, while it was 76.5 (71.0-81.0) years for the control group. At twelve weeks post-randomization, the intergroup difference in the mean change (95% CI) in twenty-four hour urinary frequency was -3.66 (-4.99, -2.33) with a significant decrease in the Vibegron group. Significant improvements were noted in the International Prostate Symptom Score, Overactive Bladder Questionnaire score, Overactive Bladder Symptom Score, and IPSS storage score for the Vibegron group. Additionally, in the Vibegron group the voided volume per micturition increased.
Therefore, the treatment with fifty mg of Vibegron once a day for a duration of twelve weeks resulted in notable enhancement in bladder storage symptoms associated with overactive OAB after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period.
According to a recent study, the administration of fifty mg of Vibegron once daily for twelve weeks exhibited significant improvement in bladder storage symptoms related to overactive bladder (OAB) following laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period. The findings of this study were published in the journal, Lower Urinary Tract Symptoms.Split into two groups: one group received Vibegron 50 mg once daily, while the other group had no treatment and were only followed up for 12 weeks.The median age (interquartile range) was 75.5 (72.5-78.5) years for the Vibegron group, while it was 76.5 (71.0-81.0) years for the control group. At twelve weeks post-randomization, the intergroup difference in the mean change (95% CI) in twenty-four hour urinary frequency was -3.66 (-4.99, -2.33) with a significant decrease in the Vibegron group. Significant improvements were noted in the International Prostate Symptom Score, Overactive Bladder Questionnaire score, Overactive Bladder Symptom Score, and IPSS storage score for the Vibegron group. Additionally, in the Vibegron group the voided volume per micturition increased.
Therefore, the treatment with fifty mg of Vibegron once a day for a duration of twelve weeks resulted in notable enhancement in bladder storage symptoms associated with overactive OAB after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period.
According to a recent study, the administration of fifty mg of Vibegron once daily for twelve weeks exhibited significant improvement in bladder storage symptoms related to overactive bladder (OAB) following laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period. The findings of this study were published in the journal, Lower Urinary Tract Symptoms.Split into two groups: one group received Vibegron 50 mg once daily, while the other group had no treatment and were only followed up for 12 weeks.The median age (interquartile range) was 75.5 (72.5-78.5) years for the Vibegron group, while it was 76.5 (71.0-81.0) years for the control group. At twelve weeks post-randomization, the intergroup difference in the mean change (95% CI) in twenty-four hour urinary frequency was -3.66 (-4.99, -2.33) with a significant decrease in the Vibegron group. Significant improvements were noted in the International Prostate Symptom Score, Overactive Bladder Questionnaire score, Overactive Bladder Symptom Score, and IPSS storage score for the Vibegron group. Additionally, in the Vibegron group the voided volume per micturition increased.
Therefore, the treatment with fifty mg of Vibegron once a day for a duration of twelve weeks resulted in notable enhancement in bladder storage symptoms associated with overactive OAB after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia when compared to the untreated follow-up period.
A recent study demonstrated that prostatic urethral lift (PUL) offers benefits compared to control interventions, showing promising potential for managing benign prostatic hyperplasia (BPH). This study findings were published in the journal, Archivio italiano di urologia, andrologia.
Cochrane CENTRAL, EBSCO, MEDLINE, ScienceDirect, and Google Scholar databases were searched using relevant terms related to PUL and BPH. Only randomized controlled trials (RCTs) from 2013 to 2023 were considered, following the PRISMA checklist. The assessment focused on lower urinary tract symptoms (LUTS), sexual function, quality of life, and adverse events within 3 months. Post-treatment mean values were compared with Sham (controls), and the progress from baseline to post-treatment follow-up duration was considered. The statistical analysis and assessment of bias risk were carried out with Review Manager 5.4.1, showcasing findings in terms of mean difference (MD) and risk ratios (RR).
A meta-analysis involving 378 confirmed BPH patients across 7 RCTs and utilizing a Random Effects Model revealed significant improvements in the PUL arm. These improvements included international prostate symptom score (IPSS) (MD 5.51, p<0.0001), maximum urinary flow rate (Qmax) (MD 2.13, p=0.0001), IPSS-QoL (MD 1.50, p<0.0001), and BPH Impact Index (BPHII) (MD 2.14, p=0.0001) . There was no significant increase in adverse events (RR 1.51; p=0.50). Additionally, positive outcomes were observed in post-void residual measurements and sexual function variables when post-treatment values were compared to baseline.
The above study showed that PUL provides benefits when compared to control treatments, displaying promising potential for the management of BPH.
A recent study demonstrated that prostatic urethral lift (PUL) offers benefits compared to control interventions, showing promising potential for managing benign prostatic hyperplasia (BPH). This study findings were published in the journal, Archivio italiano di urologia, andrologia.
Cochrane CENTRAL, EBSCO, MEDLINE, ScienceDirect, and Google Scholar databases were searched using relevant terms related to PUL and BPH. Only randomized controlled trials (RCTs) from 2013 to 2023 were considered, following the PRISMA checklist. The assessment focused on lower urinary tract symptoms (LUTS), sexual function, quality of life, and adverse events within 3 months. Post-treatment mean values were compared with Sham (controls), and the progress from baseline to post-treatment follow-up duration was considered. The statistical analysis and assessment of bias risk were carried out with Review Manager 5.4.1, showcasing findings in terms of mean difference (MD) and risk ratios (RR).
A meta-analysis involving 378 confirmed BPH patients across 7 RCTs and utilizing a Random Effects Model revealed significant improvements in the PUL arm. These improvements included international prostate symptom score (IPSS) (MD 5.51, p<0.0001), maximum urinary flow rate (Qmax) (MD 2.13, p=0.0001), IPSS-QoL (MD 1.50, p<0.0001), and BPH Impact Index (BPHII) (MD 2.14, p=0.0001) . There was no significant increase in adverse events (RR 1.51; p=0.50). Additionally, positive outcomes were observed in post-void residual measurements and sexual function variables when post-treatment values were compared to baseline.
The above study showed that PUL provides benefits when compared to control treatments, displaying promising potential for the management of BPH.
A recent study demonstrated that prostatic urethral lift (PUL) offers benefits compared to control interventions, showing promising potential for managing benign prostatic hyperplasia (BPH). This study findings were published in the journal, Archivio italiano di urologia, andrologia.
Cochrane CENTRAL, EBSCO, MEDLINE, ScienceDirect, and Google Scholar databases were searched using relevant terms related to PUL and BPH. Only randomized controlled trials (RCTs) from 2013 to 2023 were considered, following the PRISMA checklist. The assessment focused on lower urinary tract symptoms (LUTS), sexual function, quality of life, and adverse events within 3 months. Post-treatment mean values were compared with Sham (controls), and the progress from baseline to post-treatment follow-up duration was considered. The statistical analysis and assessment of bias risk were carried out with Review Manager 5.4.1, showcasing findings in terms of mean difference (MD) and risk ratios (RR).
A meta-analysis involving 378 confirmed BPH patients across 7 RCTs and utilizing a Random Effects Model revealed significant improvements in the PUL arm. These improvements included international prostate symptom score (IPSS) (MD 5.51, p<0.0001), maximum urinary flow rate (Qmax) (MD 2.13, p=0.0001), IPSS-QoL (MD 1.50, p<0.0001), and BPH Impact Index (BPHII) (MD 2.14, p=0.0001) . There was no significant increase in adverse events (RR 1.51; p=0.50). Additionally, positive outcomes were observed in post-void residual measurements and sexual function variables when post-treatment values were compared to baseline.
The above study showed that PUL provides benefits when compared to control treatments, displaying promising potential for the management of BPH.
According to a new study, Tamsulosin 0.8 mg has demonstrated superior efficacy in managing lower urinary tract symptoms caused by benign prostatic enlargement compared to Tamsulosin 0.4 mg, and it is well tolerated by patients. This study was published in the journal, International Urology and Nephrology.
In this study, ninety-three patients who met the criteria were allocated randomly into two groups: Group A, who received Tamsulosin 0.4 mg/day, and Group B, who received Tamsulosin 0.8 mg/day. The post void residual urine volume, international prostate symptom score and maximum flow rate of urine were measured before and after 4 weeks of treatment
Both study groups exhibited a notable decline in storage sub-score but only Group B demonstrated a significant decrease in frequency (P < 0.001).Tamsulosin 0.8 mg was found to be superior to Tamsulosin 0.4 mg in terms of voiding sub-score, except for straining (P = 0.325). The total international prostate symptom score exhibited a significant improvement in Group B when compared to Group A (P < 0.001). Additionally, maximum flow rate and post-void residual urine volume were notably improved in Group B when compared to Group A (P < 0.001).
Thus, it can be concluded that Tamsulosin 0.8 mg is more effective than Tamsulosin 0.4 mg in addressing lower urinary tract symptoms caused by benign prostatic enlargement, and patients tolerate it well.
According to a new study, Tamsulosin 0.8 mg has demonstrated superior efficacy in managing lower urinary tract symptoms caused by benign prostatic enlargement compared to Tamsulosin 0.4 mg, and it is well tolerated by patients. This study was published in the journal, International Urology and Nephrology.
In this study, ninety-three patients who met the criteria were allocated randomly into two groups: Group A, who received Tamsulosin 0.4 mg/day, and Group B, who received Tamsulosin 0.8 mg/day. The post void residual urine volume, international prostate symptom score and maximum flow rate of urine were measured before and after 4 weeks of treatment
Both study groups exhibited a notable decline in storage sub-score but only Group B demonstrated a significant decrease in frequency (P < 0.001).Tamsulosin 0.8 mg was found to be superior to Tamsulosin 0.4 mg in terms of voiding sub-score, except for straining (P = 0.325). The total international prostate symptom score exhibited a significant improvement in Group B when compared to Group A (P < 0.001). Additionally, maximum flow rate and post-void residual urine volume were notably improved in Group B when compared to Group A (P < 0.001).
Thus, it can be concluded that Tamsulosin 0.8 mg is more effective than Tamsulosin 0.4 mg in addressing lower urinary tract symptoms caused by benign prostatic enlargement, and patients tolerate it well.
According to a new study, Tamsulosin 0.8 mg has demonstrated superior efficacy in managing lower urinary tract symptoms caused by benign prostatic enlargement compared to Tamsulosin 0.4 mg, and it is well tolerated by patients. This study was published in the journal, International Urology and Nephrology.
In this study, ninety-three patients who met the criteria were allocated randomly into two groups: Group A, who received Tamsulosin 0.4 mg/day, and Group B, who received Tamsulosin 0.8 mg/day. The post void residual urine volume, international prostate symptom score and maximum flow rate of urine were measured before and after 4 weeks of treatment
Both study groups exhibited a notable decline in storage sub-score but only Group B demonstrated a significant decrease in frequency (P < 0.001).Tamsulosin 0.8 mg was found to be superior to Tamsulosin 0.4 mg in terms of voiding sub-score, except for straining (P = 0.325). The total international prostate symptom score exhibited a significant improvement in Group B when compared to Group A (P < 0.001). Additionally, maximum flow rate and post-void residual urine volume were notably improved in Group B when compared to Group A (P < 0.001).
Thus, it can be concluded that Tamsulosin 0.8 mg is more effective than Tamsulosin 0.4 mg in addressing lower urinary tract symptoms caused by benign prostatic enlargement, and patients tolerate it well.
